Sanofi’s Viehbacher enthusiastic about new biotech pacts; Argos yanks IPO; Telaprevir effective in HIV patients

@FierceBiotech: Protein-based nanofiber envisioned for use in delivering cardio, Alzheimer's drugs. Story | Follow @FierceBiotech

@JohnCFierce: Mersana does an ADC development deal with Endo--$270M in biobucks. Release | Follow @JohnCFierce

@RyanMFierce: Not surprised. Accelrys (software for drug discovery labs) barely topped analyst EPS estimates for 4Q '11. More | Follow @RyanMFierce

> Continuing to speak out on one of his favorite themes, Sanofi ($SNY) CEO Chris Viehbacher told a conference in Boston that he's particularly enthusiastic about striking up new collaborations with biotech companies as a way to drive innovation at the pharma giant. After scaling down internal R&D, Sanofi has been looking externally for new and better therapies in the biotech pipeline. Story

> GE Healthcare has acquired Xcellerex, a biopharmaceutical manufacturer with expertise in recombinant proteins, antibodies and vaccines. No financial terms were disclosed. Release

> New data demonstrates that two new hepatitis C drugs from Vertex Pharmaceuticals ($VTRX) and Merck ($MRK) are effective in patients who are also infected with HIV. The Vertex drug, telaprevir, proved superior. Story

> Argos Therapeutics has yanked its IPO, citing market conditions. MedCity News reports that Argos will have to find some other way to fund Phase III cancer studies. Report

> As part of the buyout deal with Amgen ($AMGN), Micromet CEO Christian Itin and the rest of the executive team have resigned and been replaced by Amgen execs. Story

Pharma News

@FiercePharma: GSK's 19%-owned Aspen Pharmacare grew first-half sales 31% as Asia-Pacific revenues triple--Reuters. Article | Follow @FiercePharma

> Pradaxa patient's death draws more scrutiny of bleeding risks. Story

> Whistleblower claims Takeda blunted Actos heart reports. News

Medical Device News

> Abbott, Merck keep companion Dx trend going with cancer test. Article

> Accelmed, Peregrine Ventures pump up NLT Spine's funding to $14.5M. News

> FDA warns Synthes facility over complaint handling procedures. More

> Roche tries to pressure Illumina to start talking. Item

Biomarkers News

> Biomarkers warn of kidney injury after heart surgery. Story

> Biomarkers expose child cancer treatment heart risk. Article

> Mitochondria changes could track Alzheimer's disease. More

> Urine test could point out colon cancers. Item

Drug Delivery News

> Conceal drug delivery tech to avoid immune system wrath. Story

> With J&J deal undone, Orexo revamps drug delivery tech development. More

> Tekmira seeks court's rejection of Alnylam drug delivery patent suit. Article

> Protein-based nanofiber envisioned for drug delivery use. Item

And Finally… Boston-based Akili Interactive, which is being incubated at PureTech, is developing new therapeutic video games. Report

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.